Non-invasive Measures of Distal Lung Disease in Asthmatics
Information source: Teva Pharmaceutical Industries
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: QVAR (Drug); Advair (Drug); Servent Diskus (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Teva Branded Pharmaceutical Products, R&D Inc. Official(s) and/or principal investigator(s): Michelle Zeidler, MD, Principal Investigator, Affiliation: University of California, Los Angeles
Summary
This is a Phase 4, single center study conducted in mild-to moderate asthmatics.
Clinical Details
Official title: Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Therapy Directed at the Proximal vs. Distal Lung
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: High resolution Cat Scans
Detailed description:
The study consists of 3 phases. There are 7 study visits.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18-65 years old
- Currently using SABA prn or a low-to-moderate persistent asthma
Exclusion Criteria:
- Tobacco use within 1 year or >= 5 pack years
Locations and Contacts
UCLA, Los Angeles, California 90095, United States
Additional Information
Starting date: September 2005
Last updated: March 19, 2015
|